Top Institutional Investors

Rhenman & Partners Asset Management AB — 13F Holdings & Portfolio

CIK 1599882 · latest 13F-HR filed 2026-08-13

Backtest portfolio

Rhenman & Partners Asset Management AB manages $1.06B in 13F-reported U.S. long-equity assets across 99 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are UNH (3.67%), CVS (2.73%), AZN (2.69%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 21 new positions and exited 8; 49 existing positions rose in reported value and 21 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$1.06B

Long-equity book

Holdings
99

Distinct positions

Period
2026-06-30

Filed 2026-08-13

Q/Q Activity
+21 / −8 / ↑49 / ↓21

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
UNH3.7% · +106%CVS2.7% · -17%AZN2.7% · newMRK2.6% · newLLY2.5% · -34%ABBV2.3% · +35%ALHC2.2% · -5%EW2.2% · +60%GILD2.1% · +6%JAZZ2.0% · +15%BIIB1.9% · -13%SYK1.9% · +36%BSX1.8% · -28%JNJ1.7% · newGH1.6% · -21%REGN1.6% · -43%GKOS1.6% · +42%BMRN1.6% · +40%NRIX1.6% · +118%NTRA1.6% · +18%MIRM1.5% · +50%INSM1.5% · -5%THC1.5% · +58%TMO1.5% · -24%CNC1.5% · newAXSM1.5% · -1%DHR1.4% · +345%VRTX1.4% · -29%AVR1.4% · +7%NBIX1.4% · -15%PNTG1.3% · +35%ISRG1.3% · -6%ELV1.3% · +8%LIVN1.3% · +6%COR1.2% · -11%CRL1.2% · +120%IDYA1.2% · +35%MCK1.2% · -2%SNDX1.2% · +48%BTSG1.1% · +232%MDT1.1% · +61%MLYS1.1% · +58%OSCR1.1% · -41%RPRX1.0% · -16%DXCM1.0% · newALGN1.0% · +740%SYRE1.0% · newRLAY1.0% · +57%ARWR1.0% · -11%A0.9% · +200%NKTR0.9% · +139%ALKS0.9% · +39%ABT0.8% · -14%DNTH0.8% · +6%PRCT0.7% · -27%GPCR0.7% · +13%ORKA0.7% · newEHC0.7% · +32%MLTX0.7% · +61%IOVA0.7% · -17%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 25.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

Name Title / Status Ownership Type

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Rhenman & Partners Asset Management AB Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 UNITED HEALTH GROUP INC UNH 91324P102 $38.9M 3.67% 93,600 SH
2 CVS HEALTH CORP CVS 126650100 $28.9M 2.73% 279,374 SH
3 ASTRAZENECA PLC AZN G0593M107 $28.5M 2.69% 151,500 SH
4 MERCK & CO INC MRK 58933Y105 $27.4M 2.59% 213,500 SH
5 LILLY ELI & CO LLY 532457108 $26.8M 2.53% 22,315 SH
6 ABBVIE INC ABBV 00287Y109 $24.4M 2.30% 96,775 SH
7 ALIGNMENT HEALTHCARE INC ALHC 01625V104 $23.7M 2.24% 997,083 SH
8 EDWARDS LIFESCIENCES CORP EW 28176E108 $23.5M 2.22% 260,000 SH
9 GILEAD SCIENCES INC GILD 375558103 $22.5M 2.13% 178,250 SH
10 JAZZ PHARMACEUTICALS PLC JAZZ G50871105 $21.1M 1.99% 87,440 SH
11 BIOGEN INC BIIB 09062X103 $20.5M 1.93% 94,850 SH
12 STRYKER CORPORATION SYK 863667101 $20.5M 1.93% 65,000 SH
13 BOSTON SCIENTIFIC CORP BSX 101137107 $19.2M 1.81% 450,500 SH
14 JOHNSON & JOHNSON JNJ 478160104 $18.4M 1.74% 72,500 SH
15 GUARDANT HEALTH INC GH 40131M109 $17.3M 1.63% 115,000 SH
16 REGENERON PHARMACEUTICALS REGN 75886F107 $17.1M 1.61% 27,390 SH
17 GLAUKOS CORP GKOS 377322102 $16.6M 1.57% 119,000 SH
18 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $16.6M 1.57% 290,500 SH
19 NURIX THERAPEUTICS INC NRIX 67080M103 $16.6M 1.57% 684,250 SH
20 NATERA INC NTRA 632307104 $16.6M 1.56% 61,050 SH
21 MIRUM PHARMACEUTICALS INC MIRM 604749101 $16.3M 1.54% 139,205 SH
22 INSMED INC INSM 457669307 $16.2M 1.53% 151,960 SH
23 TENET HEALTHCARE CORP THC 88033G407 $15.9M 1.50% 85,200 SH
24 THERMO FISHER SCIENTIFIC INC TMO 883556102 $15.8M 1.49% 31,580 SH
25 CENTENE CORP DEL CNC 15135B101 $15.7M 1.48% 244,000 SH
26 AXSOME THERAPEUTICS INC. AXSM 05464T104 $15.4M 1.46% 63,050 SH
27 DANAHER CORPORATION DHR 235851102 $15.3M 1.44% 80,252 SH
28 VERTEX PHARMACEUTICALS INC VRTX 92532F100 $15.2M 1.44% 30,685 SH
29 ANTERIS TECHNOLOGIES GLOBAL AVR 03675P102 $15.2M 1.43% 1,538,625 SH
30 NEUROCRINE BIOSCIENCES INC NBIX 64125C109 $14.5M 1.37% 85,841 SH
31 PENNANT GROUP INC PNTG 70805E109 $13.7M 1.30% 371,471 SH
32 INTUITIVE SURGICAL INC ISRG 46120E602 $13.7M 1.30% 34,500 SH
33 ELEVANCE HEALTH INC ELV 036752103 $13.5M 1.27% 34,900 SH
34 LIVANOVA PLC LIVN G5509L101 $13.5M 1.27% 164,000 SH
35 CENCORA INC COR 03073E105 $13.2M 1.25% 46,778 SH
36 CHARLES RIV LABS INTL INC CRL 159864107 $13.0M 1.22% 57,200 SH
37 IDEAYA Biosciences Inc IDYA 45166A102 $12.8M 1.21% 343,800 SH
38 MCKESSON CORP MCK 58155Q103 $12.5M 1.18% 16,550 SH
39 SYNDAX PHARMACEUTICALS INC SNDX 87164F105 $12.2M 1.16% 560,250 SH
40 BRIGHTSPRING HEALTH SVCS INC BTSG 10950A106 $11.6M 1.09% 165,896 SH
41 MEDTRONIC PLC MDT G5960L103 $11.3M 1.07% 145,000 SH
42 MINERALYS THERAPEUTICS INC MLYS 603170101 $11.2M 1.06% 416,371 SH
43 OSCAR HEALTH INC OSCR 687793109 $11.2M 1.06% 392,000 SH
44 ROYALTY PHARMA PLC RPRX G7709Q104 $11.0M 1.04% 197,000 SH
45 DEXCOM INC DXCM 252131107 $10.8M 1.02% 160,000 SH
46 ALIGN TECHNOLOGY INC ALGN 016255101 $10.6M 1.00% 63,000 SH
47 SPYRE THERAPEUTICS INC SYRE 00773J202 $10.6M 1.00% 119,300 SH
48 RELAY THERAPEUTICS INC RLAY 75943R102 $10.6M 1.00% 566,000 SH
49 ARROWHEAD PHARMACEUTICALS IN ARWR 04280A100 $10.4M 0.98% 128,000 SH
50 AGILENT TECHNOLOGIES INC A 00846U101 $10.0M 0.94% 75,000 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-13 $1.06B 99 0001213900-26-088652
2026-03-31 2026-05-14 $810.5M 86 0001213900-26-056196
2025-12-31 2026-02-13 $1.07B 94 0001213900-26-015821
2025-09-30 2025-11-13 $903.7M 92 0001213900-25-109534
Filer Information
Address
STRANDVAGEN 5A
STOCKHOLM 11451
Phone
(468) 459-8880
Filing Manager
Rhenman & Partners Asset Management AB
Stockholm, V7
Signatory
Teresa Isele
CEO